> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Cidara Therapeutics Rezafungin NDA
- URL: https://www.fdaweb.com/panel-to-discuss-cidara-therapeutics-rezafungin-nda/
- Published: 2022-11-28T12:00:00.000Z
- Updated: 2026-09-14T18:07:42.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5153265

*Federal Register* notice: FDA has announced a 1/24 Antimicrobial Drugs Advisory Committee meeting. Panel members are scheduled to a discuss a Cidara Therapeutics NDA for rezafungin lyophilized powder for injection, indicated for treating *candidemia* and invasive *candidiasis* in adults. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-11-25/pdf/2022-25643.pdf?ref=fdaweb.com).